Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

There is zero evidence that ​​semaglutides can increase the size of your crown jewels. What may happen is that as you lose ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

This Is Us star Chrissy Metz reflects on her struggles with her body image and self-worth, and shares her thoughts on weight ...

The Hunting Wives' actress Chrissy Metz gets candid in a new cover story for PEOPLE on her thoughts about using weight loss ...

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed ...